Correspondence 0001193125-24-021092 from Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc.
Date: Jan. 31, 2024 · CIK: 0001796280 · Accession: 0001193125-24-021092
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276719
Letter
ORIC Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, California 94080
January 31, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller, Staff Attorney
Re: ORIC Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-276719
Acceleration Request
Requested Date: February 2, 2024
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-276719) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Amanda Urquiza at (650) 849-3032.
[Signature page follows]
Sincerely,
ORIC Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ORIC Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, California 94080 January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Staff Attorney Re: ORIC Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-276719 Acceleration Request Requested Date: February 2, 2024 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, ORIC Pharmaceuticals, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-276719) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Amanda Urquiza at (650) 849-3032. [Signature page follows] Sincerely, ORIC Pharmaceuticals, Inc. /s/ Jacob M. Chacko, M.D. Jacob M. Chacko, M.D. President and Chief Executive Officer cc: Christian Kuhlen, ORIC Pharmaceuticals, Inc. Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C. Amanda N. Urquiza, Wilson Sonsini Goodrich & Rosati, P.C.